Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA

Carcinoma Clinical Trial

Official title: A Prospective Study of Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA

Status Active, not recruiting

Clinical Trial Summary

Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations. This study is to evaluate the feasibility and application value by using NGS into identifying genomic mutations in multiple or multifocal primary lung cancers in cell-tumor DNA (ctDNA) from surgical patients

Clinical Trial Description

Tumor samples originating from clinically considered multiple or multifocal primary lung cancer patients were available for mutational analysis. DNA and RNA were extracted from fresh tumor tissue or formalin-fixed, paraffin-embedded (FFPE) tissue. A series of cancer-related genomic alterations including single nucleotide variations (SNVs), short insertions and deletions (InDels), copy number variations (CNVs) and gene rearrangements were identified by a comprehensive NGS Panal . High frequency mutations were also identified in blood sample by droplet digital polymerase chain reaction(ddPCR). ;

Related Conditions & MeSH terms

• Carcinoma
• Lung Neoplasms
• Non-small-cell Lung Cancer
• Thoracic Neoplasms

• NCT number: NCT02833467
• Study type: Observational
• Source: Peking University People's Hospital
• Status: Active, not recruiting
• Start date: January 2015
• Completion date: June 2021